Answers are grounded in this paper and cite their sources.
Cancer vaccines have garnered significant attention in cancer immunotherapy because they trigger tumor-specific immune responses. However, their effectiveness is hindered by inefficient antigen and adjuvant delivery at the subcellular level, which is essential to stimulate a robust CD8 + T cell response. This study presents PAR/OVA, a cancer nanovaccine developed by combining imiquimod (R837)-modified polyamidoamine dendrimers with the model protein antigen ovalbumin (OVA). Within the nanovaccine, R837 is an adjuvant for the Toll-like receptor 7 (TLR7) pathway and a structural component that facilitates OVA loading. In dendritic cells (DCs), the high cytoplasmic glutathione levels triggered the breakdown of PAR/OVA, releasing OVA and R837, which induced DC activation and antigen cross-presentation. Furthermore, PAR/OVA vaccination showed a protective effect and effectively inhibited B16-OVA tumor progression, indicating its potential in cancer immunotherapy. Combining this vaccine with an immune checkpoint blockade enhanced antitumor efficacy by improving the ability of cytotoxic T lymphocytes to target cancer cells within the tumor microenvironment. These findings underscore the potential of this adjuvant/antigen-delivering nanovaccine in cancer immunotherapy.
No takes yet. Share an insight, caveat, or question.
He et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: